Skip to main content

Table 2 Comparison of main TEAEs between different doses of lasmiditan and placebo

From: Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

Outcome or SubgroupStudiesParticipantsRisk Ratio (M-H, Fixed, 95% CI)PI2
Dizziness471255.81 [4.72, 7.14]<0.0000167%
 <50 mg11301.75 [0.77, 3.99]0.18/
 50 mg214674.55 [2.70, 7.67]<0.0000170%
 100 mg326955.75 [4.10, 8.06]<0.0000169%
 200 mg326776.59 [4.72, 9.21]<0.0000157%
 400 mg115664.94 [4.03, 1047.06]0.003/
Nausea369952.58 [1.87, 3.57]<0.000010%
 50 mg214672.63 [1.20, 5.75]0.450%
 100 mg326952.37 [1.42, 3.94]0.000941%
 200 mg326772.54 [1.54, 4.21]0.00030%
 400 mg115613.48 [0.76, 239.65]0.08/
Fatigue471255.38 [3.78, 7.66]<0.0000129%
 <50 mg11301.19 [0.40, 3.58]0.75/
 50 mg214673.52 [1.62, 7.64]0.0010%
 100 mg326956.99 [3.62, 13.48]<0.000010%
 200 mg326776.77 [3.51, 13.07]<0.000010%
 400 mg11569.83 [2.34, 41.31]0.002/
Paraesthesia471254.48 [3.33, 6.02]<0.0000113%
 <50 mg113020.78 [1.29, 334.92]0.03/
 50 mg214672.24 [0.98, 5.14]0.060%
 100 mg326953.90 [2.43, 6.26]<0.0000121%
 200 mg326775.03 [3.17, 7.99]<0.000010%
 400 mg11568.60 [2.02, 36.58]0.004/
Somnolence369952.82 [2.18, 3.66]<0.000010%
 50 mg214672.86 [1.60, 5.09]0.040%
 100 mg326952.59 [1.70, 3.95]<0.000010%
 200 mg326772.92 [1.92, 4.42]<0.000010%
 400 mg11564.91 [1.08, 22.40]0.0004/
\